Time to benefit and the long-term persistence of new users of oral bisphosphonates

Friesen, Kevin J.; Bugden, Shawn; Falk, Jamie

doi:10.1007/s00774-019-01069-x

Cited by 7 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Remarkably, a study of FLS in France reported a 1-year adherence rate of less than 50% among patients aged 70 years or older; 28 this may be owing to differences in study design. The 3-year adherence rate in an observational study of patients who did not receive FLS was 25%, 25 which is comparable to the rate in our study (26%). Naranjo et al observed that approximately 57% of patients adhered to treatment for 3 years, 26 similar to our findings (57.5%).…”

Section: Discussionsupporting

confidence: 85%

“…Thus, in comparison with those who did not receive OWFLS, adherence was better in patients included in OWFLS (p ¼ 0.003, p < 0.0001, respectively). A large population-based study including 42,249 patients who did not receive FLS revealed that only 48% adhered to bisphosphonate treatment for 1 year, 25 which is similar to the 1-year adherence rate among patients who did not receive OWFLS in our study (51.9%). Naranjo et al discovered that the 1-year adherence rate for FLS recipients was 72%.…”

Section: Discussionsupporting

confidence: 85%

See 1 more Smart Citation

Three-year follow-up of a novel orthopedic ward fracture liaison services (OWFLS) model

Cai,

Ying,

Zhang

et al. 2024

J Int Med Res

View full text Add to dashboard Cite

Objective We established an orthopedic ward fracture liaison services (OWFLS) model and evaluated its role in improving detection rates of bone metabolic markers, treatment rates, and long-term treatability. Methods This observational retrospective cohort study included 120 patients aged >50 years hospitalized for primary osteoporotic fracture from January 2018 to January 2019 (group A: not included in OWFLS). Group B (included in OWFLS) comprised 120 patients from February 2019 to February 2020. We compared rates of bone metabolic index testing, treatment, and adherence; symptomatic improvement; and recurrent fracture between groups. Results Rates of bone metabolism index testing (50% vs. 0%) and medication use (94.2% vs. 64.2%) were significantly higher after OWFLS implementation. There was no significant difference in adherence rates at 3 months between groups (97.3% vs. 93.5%). Adherence rates at 1 and 3 years were better in group B than A (73.5% vs. 51.9%; 57.5% vs. 26%, respectively). Recurrence of bone pain at 1 and 3 years was significantly lower in group B than A (20.4% vs. 46.8%; 45.1% vs. 76.6%, respectively). Conclusions OWFLS improved the detection rate of bone metabolism indicators, treatment rate, and patient adherence and reduced recurrence of bone pain. OWFLS may be suitable for settings lacking human resources.

show abstract

Section: Discussionsupporting

confidence: 85%

Section: Discussionsupporting

confidence: 85%

Three-year follow-up of a novel orthopedic ward fracture liaison services (OWFLS) model

Cai,

Ying,

Zhang

et al. 2024

J Int Med Res

View full text Add to dashboard Cite

show abstract

“…There are few studies on adherence to osteoporosis treatment over 2 years, and none report on the FLS model. An observational study with a large sample showed that 25% of incident users of bisphosphonates continued taking treatment for up to 3 years and 14% for up to 5 years 24 . In the randomized SOS study, adherence at 3 years was 46% 25 , while in the SCOOP trial, adherence at 5 years was 26% 26 .…”

Section: Discussionmentioning

confidence: 99%

Long-term persistence of treatment after hip fracture in a fracture liaison service

Naranjo

Molina

Quevedo

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Long-term adherence to antiosteoporosis medication (AOM) in the setting of a fracture liaison service (FLS) are not well known. Patients ≥ 50 with hip fracture seen in an FLS and recommended for treatment to prevent new fractures were analyzed. Baseline data included demographics, identification mode, previous treatment and FRAX items. Patient records were reviewed 3–8 years later, and these data were collected: (1) survival; (2) major refracture; (3) initiation of treatment, proportion of days covered (PDC) and persistence with AOM. 372 patients (mean age, 79 years; 76% women) were included. Mean follow-up was 47 months, 52 patients (14%) had a refracture (22 hip) and 129 (34.5%) died. AOM was started in 283 patients (76.0%). Factors associated with initiation of AOM were previous use of bisphosphonate (OR 9.94; 95% CI 1.29–76.32) and a lower T-score lumbar (OR 0.80; 95% CI 0.65–0.99). Persistence decreased to 72.6%, 60% and 47% at 12, 36 and 60 months. A PDC > 80% was confirmed in 208 patients (55.7%) and associated with previous use of bisphosphonate (OR 3.38; 95% CI 1.34–8.53), treatment with denosumab (OR 2.69; 95% CI:1.37–5.27), and inpatient identification (OR 2.26; 95% CI 1.18–4.34). Long-term persistence with AOM was optimal in patients with hip fracture seen at an FLS. A PDC > 80% was associated with inpatient identification and prescription of denosumab.

show abstract

“…There are few studies on adherence to osteoporosis treatment over 2 years, and none report on the FLS model. An observational study with a large sample showed that 25% of incident users of bisphosphonates continued taking treatment for up to 3 years and 14% for up to 5 years (24). In the randomized SOS study, adherence at 3 years was 46% (25), while in the SCOOP trial, adherence at 5 years was 26% (26).…”

Section: Discussionmentioning

confidence: 99%

Long-term persistence of treatment after hip fracture in a fracture liaison service; recommending treatment during admission is more efficient

Naranjo

Molina

Quevedo

et al. 2021

Preprint

View full text Add to dashboard Cite

Background Long-term adherence to antiosteoporosis medication (AOM) in the setting of a fracture liaison service (FLS) are not well known. Methods Patients ≥50 with hip fracture seen in an FLS and recommended for treatment to prevent new fractures were analyzed. Baseline data included demographics, identification mode, previous treatment and FRAX® items. Patient records were reviewed 3-8 years later, and these data were collected: 1) survival; 2) major refracture; 3) initiation of treatment, proportion of days covered (PDC) and persistence with AOM. Results 372 patients (mean age, 79 years; 76% women) were included. Mean follow-up was 47 months, 52 patients (14%) had a refracture (22 hip) and 129 (34.5%) died. AOM was started in 283 patients (76.0%). Factors associated with initiation of AOM were previous use of bisphosphonate (OR9.94;95%CI:1.29-76.32) and a lower T-score lumbar (OR 0.80;95%CI:0.65-0.99). Persistence decreased to 72.6%, 60% and 47% at 12, 36 and 60 months. A PDC>80% was confirmed in 208 patients (55.7%) and associated with previous use of bisphosphonate (OR3.38;95%CI:1.34-8.53), treatment with denosumab (OR2.69;95%CI:1.37-5.27), and inpatient identification (OR2.26; 95%CI:1.18-4.34). Conclusions Long-term persistence with AOM was optimal in patients with hip fracture seen at an FLS. A PDC>80% was associated with inpatient identification and prescription of denosumab.

show abstract

Time to benefit and the long-term persistence of new users of oral bisphosphonates

Cited by 7 publications

References 31 publications

Three-year follow-up of a novel orthopedic ward fracture liaison services (OWFLS) model

Three-year follow-up of a novel orthopedic ward fracture liaison services (OWFLS) model

Long-term persistence of treatment after hip fracture in a fracture liaison service

Long-term persistence of treatment after hip fracture in a fracture liaison service; recommending treatment during admission is more efficient

Contact Info

Product

Resources

About